| 1101 |
Apheresis |
Allogeneic
|
B-cell Precursor Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Slovakia
|
67 |
| 1102 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
72 |
| 1103 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
52 |
| 1104 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Belgium
|
64 |
| 1105 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
68 |
| 1106 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Canada
|
56 |
| 1107 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
64 |
| 1108 |
Apheresis |
Allogeneic
|
Other Myelofibrosis/Myelosclerosis
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
55 |
| 1109 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
64 |
| 1110 |
Apheresis |
Allogeneic
|
Myelodysplastic disorder
|
Hematology
|
2025
|
Standard Therapy
|
France
|
63 |
| 1111 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
63 |
| 1112 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
20 |
| 1113 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
France
|
23 |
| 1114 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
73 |
| 1115 |
Apheresis |
Allogeneic
|
Inherited Immune System Disorder
|
Hematology
|
2025
|
Standard Therapy
|
France
|
9 |
| 1116 |
Apheresis |
Allogeneic
|
Lymphoma – DLBCL
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
55 |
| 1117 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
61 |
| 1118 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Lithuania
|
58 |
| 1119 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
73 |
| 1120 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
35 |
| 1121 |
Apheresis |
Allogeneic
|
Chronic myelomonocytic leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
65 |
| 1122 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 1123 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
66 |
| 1124 |
Apheresis |
Autologous
|
Diffuse large B-cell lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
42 |
| 1125 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Netherlands
|
65 |
| 1126 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
60 |
| 1127 |
Apheresis |
Allogeneic
|
Post Mielofibrosis
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
66 |
| 1128 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
74 |
| 1129 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
17 |
| 1130 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
72 |
| 1131 |
Apheresis |
Allogeneic
|
T-cell prolymphocytic leukemia
|
Hematology
|
2025
|
Standard Therapy
|
New Zealand
|
64 |
| 1132 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1133 |
Apheresis |
Allogeneic
|
Mielofibrosis
|
Hematology
|
2025
|
Standard Therapy
|
Finland
|
68 |
| 1134 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
35 |
| 1135 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
34 |
| 1136 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Belgium
|
63 |
| 1137 |
Apheresis |
Allogeneic
|
Mielodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
72 |
| 1138 |
Apheresis |
Allogeneic
|
Mielodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Switzerland
|
69 |
| 1139 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
52 |
| 1140 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
26 |
| 1141 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
50 |
| 1142 |
Apheresis |
Allogeneic
|
Chronic Lymphocyte Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
71 |
| 1143 |
Apheresis |
Allogeneic
|
Anaplastic Large Cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
3 |
| 1144 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
71 |
| 1145 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
29 |
| 1146 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Ukraine
|
38 |
| 1147 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
28 |
| 1148 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
46 |
| 1149 |
Apheresis |
Allogeneic
|
Hodking lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Spain
|
28 |
| 1150 |
Apheresis |
Allogeneic
|
Mielodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Slovakia
|
52 |
| 1151 |
Apheresis |
Allogeneic
|
T-NHL Angioimmunoblastic T-cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
56 |
| 1152 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
71 |
| 1153 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Italy
|
23 |
| 1154 |
Apheresis |
Allogeneic
|
Mielodysplastic syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Spain
|
69 |
| 1155 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Brazil
|
71 |
| 1156 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
36 |
| 1157 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
58 |
| 1158 |
Apheresis |
Allogeneic
|
Mielodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
68 |
| 1159 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
61 |
| 1160 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
35 |
| 1161 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
39 |
| 1162 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Serbia
|
58 |
| 1163 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
47 |
| 1164 |
Apheresis |
Allogeneic
|
Mielodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Netherlands
|
62 |
| 1165 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
69 |
| 1166 |
Apheresis |
Allogeneic
|
T-cell Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
35 |
| 1167 |
Apheresis |
Autologous
|
Central Nervous System Lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
71 |
| 1168 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
70 |
| 1169 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
61 |
| 1170 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
71 |
| 1171 |
Apheresis |
Autologous
|
T-cell lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
39 |
| 1172 |
Apheresis |
Autologous
|
Primary central nervous system lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
64 |
| 1173 |
Apheresis |
Allogeneic
|
Myelodysplastic syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
56 |
| 1174 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
65 |
| 1175 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
65 |
| 1176 |
Apheresis |
Allogeneic
|
Acute myeloid leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
60 |
| 1177 |
Apheresis |
Autologous
|
Hodgkin lymphoma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
32 |
| 1178 |
Apheresis |
Allogeneic
|
Myelodysplastic syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
67 |
| 1179 |
Apheresis |
Autologous
|
Multiple myeloma
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
56 |
| 1180 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Columbia
|
62 |
| 1181 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
46 |
| 1182 |
Apheresis |
Allogeneic
|
Mielodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
66 |
| 1183 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
46 |
| 1184 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
United Kingdom
|
33 |
| 1185 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
France
|
31 |
| 1186 |
Apheresis |
Allogeneic
|
B-Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |
| 1187 |
Apheresis |
Allogeneic
|
B-Acute Lymphoblastic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
62 |
| 1188 |
Apheresis |
Allogeneic
|
Hemophagocytic lymphohistiocytosis
|
Hematology
|
2025
|
Standard Therapy
|
Czechia
|
27 |
| 1189 |
Apheresis |
Allogeneic
|
Shwachman-Diamond Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Spain
|
11 |
| 1190 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
67 |
| 1191 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Canada
|
60 |
| 1192 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
CROATIA
|
43 |
| 1193 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
69 |
| 1194 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Austria
|
61 |
| 1195 |
Apheresis |
Allogeneic
|
Other Immune System
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
62 |
| 1196 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
74 |
| 1197 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Poland
|
63 |
| 1198 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
USA
|
66 |
| 1199 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2025
|
Standard Therapy
|
Denmark
|
50 |
| 1200 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2025
|
Standard Therapy
|
Germany
|
62 |